We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01319318
Recruitment Status : Completed
First Posted : March 21, 2011
Results First Posted : July 2, 2013
Last Update Posted : July 2, 2013
Information provided by (Responsible Party):

Brief Summary:
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.

Condition or disease Intervention/treatment
Vitrectomy Procedure: Pars Plana Vitrectomy

Study Type : Observational
Actual Enrollment : 25 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : March 2011
Primary Completion Date : June 2012
Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Care
U.S. FDA Resources

Group/Cohort Intervention/treatment
Pars Plana Vitrectomy
Pars plana vitrectomy performed in study eye on Day 0.
Procedure: Pars Plana Vitrectomy
Pars plana vitrectomy performed in study eye on Day 0.

Primary Outcome Measures :
  1. Percentage of Participants With Vitreous Cell Count of 0 [ Time Frame: Week 4 ]
    The study eye was dilated and the investigator used an instrument to count the number of visible cells in the vitreous, the jelly-like fluid that fills the back of the eye, using the following scale: 0 (no cells) best, +1 (1-10 cells), +2 (11-30 cells), +3 (31-50 cells) and +4 (>50 cells) worst.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who plan on undergoing a pars plana vitrectomy

Inclusion Criteria:

  • Require pars plana vitrectomy in at least 1 eye
  • Best corrected visual acuity in the study eye between 20/400 and 20/40

Exclusion Criteria:

  • Use of any NSAIDs (topical or systemic) within 14 days
  • Use of topical or systemic steroids within 30 days
  • Active eye infection in either eye
  • Any eye surgery within 6 months
  • Prior pars plana vitrectomy, YAG capsulotomy or uveitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01319318

United States, Texas
San Antonio, Texas, United States
Sponsors and Collaborators
Study Director: Medical Director Allergan

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01319318     History of Changes
Other Study ID Numbers: GMA-OZU-10-017
First Posted: March 21, 2011    Key Record Dates
Results First Posted: July 2, 2013
Last Update Posted: July 2, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action